SRX Global Makes Strategic Investment in Clinical-Stage Biodefense Company, ARMR Sciences
Rhea-AI Summary
SRX Global (NYSE American: SRXH) announced a strategic investment in ARMR Sciences, a clinical-stage biodefense company developing medical countermeasures against synthetic drugs like fentanyl.
ARMR’s lead candidate ARMR-100, in a Phase 1/2 trial, has generated an anti-fentanyl immune response in humans with favorable safety and aims to provide 6–12 months of protection, with the next trial phase planned for late 2026.
Positive
- SRX Global makes strategic investment in clinical-stage biodefense firm ARMR Sciences
- Lead candidate ARMR-100 shows anti-fentanyl immune response in humans
- Phase 1/2 data reported with favorable safety profile
- ARMR-100 aims for 6–12 months preventive protection against fentanyl
- Next development phase evaluating protection against fentanyl expected to begin in 2026
Negative
- ARMR-100 remains in Phase 1/2, with efficacy against fentanyl not yet demonstrated
- Company notes there is still important development work ahead before potential commercialization
News Market Reaction – SRXH
In the Jun 23 session, SRXH declined 18.73%, reflecting a significant negative market reaction. Argus tracked a trough of -17.1% from its starting point during tracking. Our momentum scanner triggered 16 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jun 18 | Acquisition & rebrand | Neutral | -28.1% | Closing EMJX deal and launching SRX Global AI-driven capital platform. |
| Jun 08 | Strategic investment | Neutral | +1.4% | Acquiring 4.99% of Smartkem and related preferred securities via shelf takedown. |
| May 29 | Portfolio update | Neutral | -4.7% | Updating positions in Uber, Compass, Bitcoin and hedging stance via EMJX model. |
| May 21 | IPO pharma investment | Neutral | +9.8% | Investment in Optimi Health, a commercial-stage psychedelic pharmaceutical company. |
| May 15 | Dividend policy update | Neutral | -9.4% | Plan to dividend 75% of profits from Astro Investment XVII to shareholders. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
phase 1/2 medical
warrants financial
pre-funded warrants financial
equity line of credit financial
asset acquisition financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
NORTH PALM BEACH, Fla., June 23, 2026 (GLOBE NEWSWIRE) -- SRX Global, Inc. (NYSE American: SRXH) (the "Company", or “SRX”) today announced a strategic investment in ARMR Sciences, a clinical-stage biodefense company developing a platform of medical countermeasures against synthetic drugs, such as fentanyl. ARMR’s lead product, ARMR-100, recently announced it has successfully generated an anti-fentanyl immune response in humans and showed favorable safety data. This marks a critical milestone in the company's path toward demonstrating that this response can protect against fentanyl.
ARMR-100 is being designed to work with the body to generate a protective immune response. The product, in a Phase 1/2 clinical trial, produces anti-fentanyl antibodies capable of binding to lethal synthetic drugs. Once the antibodies bind to the synthetic drug target, such as fentanyl, the drug is prevented from entering the brain. If the molecule is prevented from reaching the brain, then the downstream effects that lead to overdose may also be prevented. ARMR-100 is in development to be the first long-lasting preventive medication against fentanyl, with the goal that the product endures for 6-12 months in healthy adults. The next phase is evaluating protection against fentanyl, currently on track to begin later in 2026.
"I want to thank the entire team at SRX Global for their investment and belief in our vision, turning what many called impossible into a reality," said Collin Gage, CEO of ARMR Sciences. "Our recently announced positive early results are a testament to the deeply experienced team of scientists, researchers, and medical professionals we have assembled. While there is still important work ahead, we believe today's milestone further validates our approach and reinforces our confidence in the path forward as we continue advancing a potential solution that could save countless lives. We look forward to a great partnership with SRX going forward."
About ARMR Sciences
ARMR Sciences is a clinical-stage biodefense company developing a platform of medical countermeasures against synthetic drugs, including fentanyl, and other emerging chemical threats. The company's lead product, ARMR-100, is designed to generate a protective immune response that produces antibodies capable of binding synthetic molecules and blocking them from reaching the brain.
For more information, visit https://armrsciences.com
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "believe," "expect," "intend," "aim," "plan," "may," "could," "target," and similar expressions are intended to identify forward-looking statements. These statements are based on current expectations and assumptions that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied. These risks include, but are not limited to, the ability to complete the proposed transaction, shareholder approvals, market conditions, regulatory considerations, and other risks described in the Company's filings with the Securities and Exchange Commission. Forward-looking statements speak only as of the date made, and the Company undertakes no obligation to update them, except as required by law.
Company Contact
SRX Global, Inc.
Kent Cunningham, Chief Executive Officer
Investor Relations Contact
KCSA Strategic Communications
Valter Pinto, Managing Director
212-896-1254
srx@kcsa.com
